LXRX Lexicon Pharmaceuticals Inc.

7.26
+0.17  (+2%)
Previous Close 7.09
Open 7.04
Price To Book -25.93
Market Cap 769018419
Shares 105,925,402
Volume 840,887
Short Ratio
Av. Daily Volume 439,507

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154778
  2. 8-K - Current report 181151992
  3. 8-K - Current report 181053185
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18978015
  5. 8-K - Current report 18976067

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiated September 2017.
Sotagliflozin
Type 2 Diabetes
Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
PDUFA date March 22, 2019. Advisory Committee Meeting January 17, 2019.
Sotagliflozin
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
Phase 3 trial initiated 4Q 2016. Data due 2019.
Sotagliflozin
Type 2 Diabetes
Phase 1a data due 4Q 2018.
LX9211
Neuropathic pain
Phase 1b data due 4Q 2018.
LX2761
Type 2 diabetes